Clinical trial Recruiting at 1 site Interventional Ages 9 to 17

STOP-HPV scale-up to increase HPV vaccination in clinics

Official title: The STOP-HPV Scale Up Study

Run by University of California, Los Angeles · NCT06831383 · Data updated 2026-11-12

This trial will test two ways of training clinic teams to see if they increase HPV vaccine starts for 9–12 year olds at well-child visits compared with usual care.

Quick facts

Study typeInterventional
Ages9 Years to 17 Years
SexAll
Enrollment100000 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Alexandria, Virginia)
StatusRecruiting
StartedMarch 30, 2026
Main results expectedApril 19, 2027
Study endsApril 19, 2027
Registry record updatedMay 19, 2026
Trial IDNCT06831383 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged about 9 to <13 years who attend a participating practice for a well-child visit and have not yet received any HPV vaccine dose.

Probably not a fit

Patients who have already received any HPV vaccine dose or who are outside the eligible age range are unlikely to benefit from the interventions in this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a three-arm, cluster randomized trial that will randomize about 72 primary care practices across up to eight U.S. health systems to one of two implementation strategies or usual care. One arm delivers online provider communication training only (STOP-HPV-Online) and the other adds a Learning Collaborative with performance feedback for practice leads (STOP-HPV-LC); health systems will deploy the interventions with AMGA support as needed. The primary outcome is HPV vaccine initiation among 9 to <13 year olds during a 12-month intervention period, with fidelity monitoring and cost-effectiveness analysis. The design builds on prior work that produced modest improvements when interventions were delivered by the research team and tests whether those gains hold when scaled and run by health systems.

Why it matters

Potential benefit: If successful, the interventions could increase HPV vaccine initiation in age-eligible patients and thereby reduce future HPV-related cancers.

How similar studies have gone: Prior investigator-led studies showed modest increases in initiation (about 6.8% for online training and ~8% when combined with a learning collaborative), but this trial tests whether those effects can be replicated when health systems implement the strategies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient of participating practice
* Well child care visit during the 12-month intervention period
* No prior dose of HPV vaccine at the time of the well child care visit
* Age-eligible

Exclusion Criteria:

* Prior dose of HPV vaccine

Where it's running

  • Amga
    Alexandria, Virginia, United States
    Recruiting

Study contacts

  • Principal investigator: Peter Szilagyi, MD, MPH — University of California, Los Angeles
  • Study coordinator: Peter Szilagyi, MD, MPH
  • Email: pszilagyi@mednet.ucla.edu
  • Phone: 310-206-6328

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.